code stringlengths 4 12 | description stringlengths 2 264 | codetype stringclasses 8
values | context stringlengths 160 15.5k |
|---|---|---|---|
90756 | PR CCIIV4 VACCINE ANTIBIOTIC FREE 0.5 ML DOS IM USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
G0008 | PR ADMIN INFLUENZA VIRUS VAC | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
9068 | Smallpox&monkeypox vac 0. | APC | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90689 | HC IIV4 VACC INACTIVATED PRSRV FR 0.25ML DOS IM US | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90686 | INFLUENZA VIRUS VACCINE, QUADRIVALENT (IIV4), SPLIT VIRUS, PRESERVATIVE FREE, 0.5 ML DOSAGE, FOR INTRAMUSCULAR USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90682 | HC RIV4 VACC RECOMBINANT DNA PRSRV ANTIBIO FREE IM | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
2035 | Auto cell process sys | APC | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90674 | HC CCIIV4 VACCINE PRESERVATIVE FREE 0.5 ML IM USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90653 | HC FLU VACCINE ADJUVANT IM | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
9065 | Argatroban esrd dialysis | APC | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
9067 | Lutetium lu 177 dotatat t | APC | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90662 | INFLUENZA VIRUS VACCINE (IIV), SPLIT VIRUS, PRESERVATIVE FREE, ENHANCED IMMUNOGENICITY VIA INCREASED ANTIGEN CONTENT, FOR INTRAMUSCULAR USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90685 | HC IIV4 VACC PRSRV FREE 0.25 ML DOS FOR IM USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90656 | HC IIV3 VACC PRESERVATIVE FREE 0.5 ML DOSAGE IM USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
9075 | Inj, kovaltry, 1 i.u. | APC | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
Q2035 | PR AFLURIA VACC, 3 YRS & >, IM | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90688 | HC IIV4 VACC SPLIT VIRUS 0.5 ML DOS FOR IM USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90687 | Iiv4 vaccine splt 0.25 ml im | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90756 | PR CCIIV4 VACCINE ANTIBIOTIC FREE 0.5 ML DOS IM USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
G0008 | PR ADMIN INFLUENZA VIRUS VAC | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
9068 | Smallpox&monkeypox vac 0. | APC | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90689 | HC IIV4 VACC INACTIVATED PRSRV FR 0.25ML DOS IM US | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90686 | INFLUENZA VIRUS VACCINE, QUADRIVALENT (IIV4), SPLIT VIRUS, PRESERVATIVE FREE, 0.5 ML DOSAGE, FOR INTRAMUSCULAR USE | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
90682 | HC RIV4 VACC RECOMBINANT DNA PRSRV ANTIBIO FREE IM | HCPCS | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
2035 | Auto cell process sys | APC | - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadrivalent – from 18 years old and older to 5 years old... |
B4105 | Enzyme cartridge enteral nut | HCPCS | - The latest updates include 279 new codes, 51 deleted codes, and 143 revised codes. A total of 71,932 active codes have been recorded with the most recent CMS revisions. - Chapters 1, 3 and 8 witnessed no new changes whereas chapter 2,7,11,14,15,16 and 19 went through the highest changes. - HCPCS codes overhaul
- CMS ... |
B4105 | Enzyme cartridge enteral nut | HCPCS | A total of 71,932 active codes have been recorded with the most recent CMS revisions. - Chapters 1, 3 and 8 witnessed no new changes whereas chapter 2,7,11,14,15,16 and 19 went through the highest changes. - HCPCS codes overhaul
- CMS has also changed HCPCS codes Q9994, effective December 3, 2018. - The HCPCS code B410... |
B4105 | Enzyme cartridge enteral nut | HCPCS | - Chapters 1, 3 and 8 witnessed no new changes whereas chapter 2,7,11,14,15,16 and 19 went through the highest changes. - HCPCS codes overhaul
- CMS has also changed HCPCS codes Q9994, effective December 3, 2018. - The HCPCS code B4105 is changed from D "Special Coverage Instructions Apply" to C "Contractor Discretion.... |
B4105 | Enzyme cartridge enteral nut | HCPCS | - HCPCS codes overhaul
- CMS has also changed HCPCS codes Q9994, effective December 3, 2018. - The HCPCS code B4105 is changed from D "Special Coverage Instructions Apply" to C "Contractor Discretion. Code B4105 replaces code Q9994 effective for claims with dates of service on or after January 1, 2019. With the latest ... |
1744 | Endoscopic robotic assisted procedure | ICD | 2009, 30 (6): 1297-1305. 10.1016/j.ridd.2009.05.006.PubMedView ArticleGoogle Scholar
- World Health Organization (WHO): International Classification of Diseases; tenth Edition (ICD-10) Diagnostic Criteria for Research. 1993, WHO GenevaGoogle Scholar
- Bakare MO, Ubochi VN, Okoroikpa IN, Aguocha CM, Ebigbo PO: Agreement... |
E0485 | Oral device/appliance prefab | HCPCS | To qualify for coverage, the OAT service provided must be reasonable and medically necessary and in compliance with all Medicare coverage, coding, and billing requirements. Codes that are used to report OAT include the following. HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular adv... |
E0486 | Oral device/appliance cusfab | HCPCS | To qualify for coverage, the OAT service provided must be reasonable and medically necessary and in compliance with all Medicare coverage, coding, and billing requirements. Codes that are used to report OAT include the following. HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular adv... |
A9270 | NON-COVERED ITEM OR SERVICE | HCPCS | To qualify for coverage, the OAT service provided must be reasonable and medically necessary and in compliance with all Medicare coverage, coding, and billing requirements. Codes that are used to report OAT include the following. HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular adv... |
E0485 | Oral device/appliance prefab | HCPCS | Codes that are used to report OAT include the following. HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular advancement devices. - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustmen... |
E0486 | Oral device/appliance cusfab | HCPCS | Codes that are used to report OAT include the following. HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular advancement devices. - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustmen... |
A9270 | NON-COVERED ITEM OR SERVICE | HCPCS | Codes that are used to report OAT include the following. HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular advancement devices. - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustmen... |
E0485 | Oral device/appliance prefab | HCPCS | HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular advancement devices. - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
In terms of Medicare reimbursement, HCPCS code E0486 is... |
E0486 | Oral device/appliance cusfab | HCPCS | HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular advancement devices. - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
In terms of Medicare reimbursement, HCPCS code E0486 is... |
A9270 | NON-COVERED ITEM OR SERVICE | HCPCS | HCPCS codes and modifiers
Code E0486 may only be used for custom-fabricated mandibular advancement devices. - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
In terms of Medicare reimbursement, HCPCS code E0486 is... |
E0485 | Oral device/appliance prefab | HCPCS | - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
In terms of Medicare reimbursement, HCPCS code E0486 is the only reimbursable code for oral appliance therapy for OSA. Other HCPCS codes – A9270, E0485, and E1399 ... |
E0486 | Oral device/appliance cusfab | HCPCS | - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
In terms of Medicare reimbursement, HCPCS code E0486 is the only reimbursable code for oral appliance therapy for OSA. Other HCPCS codes – A9270, E0485, and E1399 ... |
A9270 | NON-COVERED ITEM OR SERVICE | HCPCS | - E0486 – Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
In terms of Medicare reimbursement, HCPCS code E0486 is the only reimbursable code for oral appliance therapy for OSA. Other HCPCS codes – A9270, E0485, and E1399 ... |
E0485 | Oral device/appliance prefab | HCPCS | Other HCPCS codes – A9270, E0485, and E1399 are not payable codes, but rather only billable codes. HCPCS modifiers for oral appliance therapy may include:
- KX: Requirements specified in the medical policy have been met
- EY: No physician order, or other licensed health care provider order, for this item or service
- G... |
A9270 | NON-COVERED ITEM OR SERVICE | HCPCS | Other HCPCS codes – A9270, E0485, and E1399 are not payable codes, but rather only billable codes. HCPCS modifiers for oral appliance therapy may include:
- KX: Requirements specified in the medical policy have been met
- EY: No physician order, or other licensed health care provider order, for this item or service
- G... |
87635 | SARS-COV-2 COVID-19 AMP PRB | HCPCS | For instance, the first new code — 87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique — was published and effective March 13, 2020. The vaccine and immunization codes may include a note i... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | The AMA posts new codes on its COVID-19 Coding and Guidance page. The page also includes links to CPT® Assistant guides for many of the codes. HCPCS Level II Codes for SARS-CoV-2/COVID-19 Services
Medicare has released HCPCS Level II codes in response to the COVID-19 pandemic, covering services such as specimen collect... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | The AMA posts new codes on its COVID-19 Coding and Guidance page. The page also includes links to CPT® Assistant guides for many of the codes. HCPCS Level II Codes for SARS-CoV-2/COVID-19 Services
Medicare has released HCPCS Level II codes in response to the COVID-19 pandemic, covering services such as specimen collect... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | HCPCS Level II Codes for SARS-CoV-2/COVID-19 Services
Medicare has released HCPCS Level II codes in response to the COVID-19 pandemic, covering services such as specimen collection and testing. Check with non-Medicare payers to confirm their policies on use and coverage of these codes. As an example, two HCPCS Level II... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | HCPCS Level II Codes for SARS-CoV-2/COVID-19 Services
Medicare has released HCPCS Level II codes in response to the COVID-19 pandemic, covering services such as specimen collection and testing. Check with non-Medicare payers to confirm their policies on use and coverage of these codes. As an example, two HCPCS Level II... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | Check with non-Medicare payers to confirm their policies on use and coverage of these codes. As an example, two HCPCS Level II codes for COVID-19 testing (U0001 and U0002) had an implementation date of April 1, 2020, which is when Medicare claims processing systems were able to accept the codes. Dates of service for th... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | Check with non-Medicare payers to confirm their policies on use and coverage of these codes. As an example, two HCPCS Level II codes for COVID-19 testing (U0001 and U0002) had an implementation date of April 1, 2020, which is when Medicare claims processing systems were able to accept the codes. Dates of service for th... |
1999 | ANESTHESIOLOGY GROUP | CPT | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
S2120 | Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation | HCPCS | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
36511 | PR THERAPEUTIC APHERESIS WHITE BLOOD CELLS | HCPCS | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
36513 | PR THERAPEUTIC APHERESIS PLATELETS | HCPCS | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
36512 | PR THERAPEUTIC APHERESIS RED BLOOD CELLS | HCPCS | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
36521 | USE 36516 | HCPCS | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
36520 | SEE 36511-36512 | HCPCS | POLICY GUIDELINESInvestigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the conditio... |
1999 | ANESTHESIOLOGY GROUP | CPT | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
S2120 | Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
36511 | PR THERAPEUTIC APHERESIS WHITE BLOOD CELLS | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
36513 | PR THERAPEUTIC APHERESIS PLATELETS | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
36512 | PR THERAPEUTIC APHERESIS RED BLOOD CELLS | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
36521 | USE 36516 | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
36520 | SEE 36511-36512 | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/19... |
1999 | ANESTHESIOLOGY GROUP | CPT | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
S2120 | Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation | HCPCS | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
36511 | PR THERAPEUTIC APHERESIS WHITE BLOOD CELLS | HCPCS | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
36513 | PR THERAPEUTIC APHERESIS PLATELETS | HCPCS | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
36512 | PR THERAPEUTIC APHERESIS RED BLOOD CELLS | HCPCS | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
36521 | USE 36516 | HCPCS | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
36520 | SEE 36511-36512 | HCPCS | POLICY HISTORY6/1993: Therapeutic Apheresis approved by Medical Policy Advisory Committee (MPAC)
11/1993: Extracorporeal Immunoadsorption Using Protein A Columns approved by MPAC
5/1999: MPAC reviewed policies; updated, combined and renamed
12/1999: Interim revision; new FDA-approved indication added for some stages of... |
36522 | PR PHOTOPHERESIS EXTRACORPOREAL | HCPCS | IgA or IgG paraproteinemia polyneuropathy added as a medically necessary indication. Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 7... |
S2120 | Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation | HCPCS | IgA or IgG paraproteinemia polyneuropathy added as a medically necessary indication. Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 7... |
86960 | HC VOL REDUC BLD/PRD EA UN | HCPCS | IgA or IgG paraproteinemia polyneuropathy added as a medically necessary indication. Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 7... |
36516 | PR THER APHERESIS W/EXTRACORPOREAL IMMUNOADSORPTION | HCPCS | IgA or IgG paraproteinemia polyneuropathy added as a medically necessary indication. Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 7... |
36515 | Apheresis adsorp/reinfuse | HCPCS | IgA or IgG paraproteinemia polyneuropathy added as a medically necessary indication. Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 7... |
36522 | PR PHOTOPHERESIS EXTRACORPOREAL | HCPCS | Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 714.0-714.9 removed; HCPCS S2120 removed. ICD-9 diagnosis codes 203.00, 203.01, 341.0,... |
S2120 | Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation | HCPCS | Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 714.0-714.9 removed; HCPCS S2120 removed. ICD-9 diagnosis codes 203.00, 203.01, 341.0,... |
86960 | HC VOL REDUC BLD/PRD EA UN | HCPCS | Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 714.0-714.9 removed; HCPCS S2120 removed. ICD-9 diagnosis codes 203.00, 203.01, 341.0,... |
36516 | PR THER APHERESIS W/EXTRACORPOREAL IMMUNOADSORPTION | HCPCS | Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 714.0-714.9 removed; HCPCS S2120 removed. ICD-9 diagnosis codes 203.00, 203.01, 341.0,... |
36515 | Apheresis adsorp/reinfuse | HCPCS | Inclusion body myositis and asthma added as investigational. Code reference section reviewed; CPT codes 36515, 36516, 36522, 86960 removed; ICD-9 procedure codes 99.76, 99.88 removed; ICD-9 diagnosis codes 202.20-202.28, 272.0-272.2, 714.0-714.9 removed; HCPCS S2120 removed. ICD-9 diagnosis codes 203.00, 203.01, 341.0,... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | - Lower respiratory infection: If the COVID-19 is documented as being associated with a lower respiratory infection, not otherwise specified (NOS), or an acute respiratory infection, NOS, this should be assigned with code J22, Unspecified acute lower respiratory infection, with code B97.29, Other coronavirus as the cau... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | - Suspected exposure with persons confirmed to have COVID-19: Assign code Z20.828, Contact with and (suspected) exposure to other viral communicable diseases. - Concern about possible exposure that is ruled out after evaluation: Assign code Z03.818, Encounter for observation for suspected exposure to other biological a... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | - Suspected exposure with persons confirmed to have COVID-19: Assign code Z20.828, Contact with and (suspected) exposure to other viral communicable diseases. - Concern about possible exposure that is ruled out after evaluation: Assign code Z03.818, Encounter for observation for suspected exposure to other biological a... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | - Concern about possible exposure that is ruled out after evaluation: Assign code Z03.818, Encounter for observation for suspected exposure to other biological agents ruled out. - Testing: There are two new HCPCS codes for healthcare providers who need to test patients for coronavirus. Providers using the Centers for D... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | - Concern about possible exposure that is ruled out after evaluation: Assign code Z03.818, Encounter for observation for suspected exposure to other biological agents ruled out. - Testing: There are two new HCPCS codes for healthcare providers who need to test patients for coronavirus. Providers using the Centers for D... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | - Testing: There are two new HCPCS codes for healthcare providers who need to test patients for coronavirus. Providers using the Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel may bill for that test using the newly created HCPCS code (U0001). A second new ... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | - Testing: There are two new HCPCS codes for healthcare providers who need to test patients for coronavirus. Providers using the Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel may bill for that test using the newly created HCPCS code (U0001). A second new ... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | Providers using the Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel may bill for that test using the newly created HCPCS code (U0001). A second new HCPCS code (U0002) can be used by laboratories and healthcare facilities to bill Medicare as well as by other... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | Providers using the Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel may bill for that test using the newly created HCPCS code (U0001). A second new HCPCS code (U0002) can be used by laboratories and healthcare facilities to bill Medicare as well as by other... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | A second new HCPCS code (U0002) can be used by laboratories and healthcare facilities to bill Medicare as well as by other health insurers that choose to adopt this new code for such tests. HCPCS code (U0002) generally describes 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19) using any technique, multiple types ... |
U0002 | HC Sars-Cov-2 Naa Coronavirus | HCPCS | HCPCS code (U0002) generally describes 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19) using any technique, multiple types or subtypes (includes all targets). The Medicare claims processing system will be able to accept these codes on April 1, 2020 for dates of service on or after Feb. 4, 2020. The CDC’s coding ... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | The Medicare claims processing system will be able to accept these codes on April 1, 2020 for dates of service on or after Feb. 4, 2020. The CDC’s coding guidance states that coders should not assign code B97.29 when the provider documents “suspected”, “possible” or “probable” COVID-19, but rather assign a code for the... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | The CDC’s coding guidance states that coders should not assign code B97.29 when the provider documents “suspected”, “possible” or “probable” COVID-19, but rather assign a code for the reason for the encounter (such as cough, fever, or Z20.828). It should be noted that the WHO has emergently implemented a new ICD-10-CM ... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | It should be noted that the WHO has emergently implemented a new ICD-10-CM code, U07.1 2019-nCoV acute respiratory disease, that will be effective with the next update on Oct. 1, 2020. CMS has developed a new Healthcare Common Procedure Coding System (HCPCS) code for providers and laboratories who test for COVID-19 usi... |
U0001 | HC NOVEL CORONAVIRUS REALT TIME PCR | HCPCS | CMS has developed a new Healthcare Common Procedure Coding System (HCPCS) code for providers and laboratories who test for COVID-19 using the 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel. CMS has indicated that the Medicare claims processing system will be able to accept HCPCS code U0001 on April 1, 20... |
1996 | Daily Hospital Management Of Epidural Or Subarachnoid Continuous Drug Administration | HCPCS | HCPCS Level III contains alphanumeric codes that are assigned
by Medicaid state agencies to identify additional items
and services not included in levels I or II. These are usually
called "local codes", and must have "W",
"X", "Y", or "Z" in the first
position. HCPCS Procedure Modifier Codes can be used with
all three ... |
1996 | Daily Hospital Management Of Epidural Or Subarachnoid Continuous Drug Administration | HCPCS | These are usually
called "local codes", and must have "W",
"X", "Y", or "Z" in the first
position. HCPCS Procedure Modifier Codes can be used with
all three levels, with the WA - ZY range used for locally
assigned procedure modifiers. - Health Insurance Portability &
Accountability Act (HIPAA) – A law passed
in 1996 wh... |
96115 | Neurobehavior status exam | HCPCS | References were updated.|
|Reviewed||08/23/2007||MPTAC review. References were updated. Coding updated; removed CPT 96115, 96117 deleted 12/31/2005.|
|Reviewed||09/14/2006||MPTAC review. References were updated.|
| ||01/01/2006||Updated coding section with 01/01/2006 CPT/HCPCS changes|
| ||11/22/2005||Added reference f... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.